Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats

Neuropsychobiology

Volumn 61, Issue 3, 2010, Pages 148-161

  Park, Sunmin ^a   Hong, Sang Mee ^a   Ahn, I L Sung ^a   Kim, Da Sol ^a   Kim, Sung Hoon ^b  

^a Hoseo University   (South Korea)

^b Kwandong University College of Medicine   (South Korea)

Author keywords

Adenosine monophosphate activated protein kinase; Diabetes; Dopamine D2 receptor antagonist; Hypothalamus; Insulin resistance; Liver; Ovariectomy

Indexed keywords

ADENOSINE PHOSPHATE; ESTRADIOL; OLANZAPINE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); PLACEBO; PROTEIN KINASE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; EPIDIDYMIS FAT; ESTROGEN THERAPY; FEMALE; FOOD INTAKE; GLUCONEOGENESIS; GLUCOSE INFUSION; GLUCOSE METABOLISM; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; NONHUMAN; OVARIECTOMY; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ADIPOSE TISSUE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIABETES MELLITUS, TYPE 2; EATING; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOSE; INSULIN RESISTANCE; LIVER; OVARIECTOMY; PANCREATECTOMY; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; WEIGHT GAIN;

EID: 76749110779     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000285780     Document Type: Article

References (38)

1. Casey DE: Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med 2005;118:15S-22S.
2. Newcomer JW, Haupt DW: The metabolic effects of antipsychotic medications. Can J Psychiatry 2006;51:480-491.
3. Goudie AJ, Cooper GD, Halford JC: Antipsychotic-induced weight gain. Diabetes Obes Metab 2005;7 478-487.
4. Aichhorn W, Whitworth AB, Weiss EM, Marksteiner J: Second-generation antipsychotics: is there evidence for sex differences in pharmacokinetic and adverse effect profiles? Drug Safety 2006 29:587-598.
5. Cope MB, Nagy TR, Fernández JR, Geary N, Casey DE, Allison DB: Antipsychotic drug-induced weight gain: development of an animal model. Int J Obes (Lond) 2005 29 607-614.
6. Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ: A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 2005;181:80-89.
7. Ader M, Kim SP, Catalano KJ, Ionut V, Hucking K, Richey JM, Kabir M, Bergman RN: Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005 54:862-871.
8. Minet-Ringuet J, Even PC, Lacroix M, Tomé D, de Beaurepaire R: A model for antipsychotic-induced obesity in the male rat. Psychopharmacology (Berl) 2006;187:447-454.
9. Cooper GD, Pickavance LC, Wilding JP, Harrold JA, Halford JC, Goudie AJ: Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol 2007;21:405-413.
10. 2 receptors in rat striatum and nucleus accumbens. Neuropharmacology 2006;50:451-457.
11. Thompson TL, Certain ME: Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. Eur J Pharmacol 2005 511:121-126.
12. Xue B, Kahn BB: AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol 2006;574:73-83.
13. Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A, Xue B, Mu J, Foufelle F, Ferré P, Birnbaum MJ, Stuck BJ, Kahn BB: AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004;428:569-574.
14. Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP: Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Ann Clin Psychiatry 2008;20:71-78.
15. Hosokawa YA, Hosokawa H, Chen C, Leahy JL: Mechanism of impaired glucose-potentiated insulin-secretion in diabetic 90 percent pancreatectomy rats - study using glucagon-like peptide-1 (7-37). J Clin Invest 1996;97:180-186.
16. American Institute of Nutrition: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 1993;123:1939-1951.
17. Frontoni S, Choi SB, Banduch D, Rossetti L: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991;40:568-573.
18. Huang AS, Beigneux A, Weil ZM, Kim PM, Molliver ME, Blackshaw S, Nelson RJ, Young SG, Snyder SH: D-Aspartate regulates MELANOCORTIN formation and function: behavioral alterations in D-aspartate oxidase-deficient mice. J Neurosci 2006;26:2814-2819.
19. Dong X, Park S, Lin X, Copps K, Yi X, White MF: Irs1 and Irs2 signaling is essential for hepatic glucose homeostasis and systemic growth. J Clin Invest 2006;116:101-114.
20. De Fronzo RA: Pathogenesis of type 2 diabetes mellitus. Med Clin North Am 2004;88:787-835.
21. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001;50:873-883.
22. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456-3459.
23. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum WA: Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 2004;83:47-54.
24. Broberger C: Brain regulation of food intake and appetite: molecules and networks. J Intern Med 2005;258:301-327.
25. Kahn B, Alquier T, Carling D, Hardie D: AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 2005;1:15-25.
26. Minokoshi Y, Kim YB, Peroni OD, Fryer LG, Muller C, Carling D, Kahn BB: Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 2002;415:339-343.
27. Choi SB, Jang JS, Park S: Estrogen and exercise may enhance β -cell function and mass via IRS2 induction in ovariectomized diabetic rats. Endocrinology 2005;146:4786-4794.
28. Kimura M, Irahara M, Yasui T, Saito S, Tezuka M, Yamano S, Kamada M, Aono T: The obesity in bilateral ovariectomized rats is related to a decrease in the expression of leptin receptors in the brain. Biochem Biophys Res Commun 2002;290:1349-1353.
29. Bryzgalova G, Lundholm L, Portwood N, Gustafsson JA, Khan A, Efendic S, Dahlman-Wright K: Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high fat diet-fed mice. Am J Physiol Endocrinol Metab 2008;295:E904-E912.
30. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, Tsai MJ, Mauvais-Jarvis F: Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 2006;103:9232-9237.
31. Haddad PM, Wieck A: Anti-psychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64:2291-2314.
32. Brelje TC, Stout LE, Bhagroo NV, Sorenson RL: Distinctive roles for prolactin and growth hormone in the activation of signal transducer and activator of transcription 5 in pancreatic islets of Langerhans. Endocrinology 2004;145:4162-4175.
33. Jackerott M, Møldrup A, Thams P, Galsgaard ED, Knudsen J, Lee YC, Nielsen JH: STAT5 activity in pancreatic beta-cells influences the severity of diabetes in animal models of type 1 and 2 diabetes. Diabetes 2006;55:2705-2712.
34. Arumugam R, Horowitz E, Lu D, Collier JJ, Ronnebaum S, Fleenor D, Freemark M: The interplay of prolactin and the glucocorticoids in the regulation of beta cell gene expression, fatty acid oxidation, and glucose-stimulated insulin secretion: implications for carbohydrate metabolism in pregnancy. Endocrinology 2008;149:5401-5414.
35. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G: Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol 2008;28:494-499.
36. Houseknecht KL, Robertson AS, Zavadoski W, Gibbs EM, Johnson DE, Rollema H: Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology 2007;32:289-297.
37. Long YC, Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006;116:1776-1783.
38. Rutter GA, Da Silva Xavier G, Leclerc I: Roles of 5′-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J 2003;375:1-16.